ArticleThe Journal of pharmacology and experimental therapeutics2025
Kidney-specific delivery of a matrix metalloproteinase-2 inhibitory peptide fused to elastin-like polypeptide reduces proteinuria and renal fibrosis in a model of salt-sensitive hypertension.
Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RhoA deficiency in chondrocyte inhibits cartilage fibrosis and ameliorates osteoarthritis progression via SOX4/MMP2 axis.Journal of orthopaedic translation · 2026Article
- Engineering Kidney-Targeted Drug Delivery Systems: Principles, Materials, and Emerging Strategies.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Renal fibrosis is the hallmark and final common pathway of chronic kidney disease. Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that cleave bioactive molecules to maintain extracellular matrix homeostasis. MMP-2 is upregulated in the progression of fibrosis in several models. We hypothesized that a renal-targeted MMP-2 inhibitor can slow the progression of renal fibrosis in a model of hypertension-induced renal injury. An MMP-2 inhibitory protein therapeutic was developed by fusing a known peptide inhibitor of MMP-2 (MMP-2i) to the elastin-like polypeptide (ELP) drug delivery system. Three sizes of the ELP carrier were tested to optimize the fusion protein's in vitro and in vivo performance. Activity and specificity of ELP-MMP-2i constructs for inhibition of MMP-2 were determined using in vitro MMP assays. Plasma clearance, organ biodistribution, renal accumulation, and intrarenal distribution of the fusion proteins were measured after intravenous and subcutaneous administration. The efficacy of the lead ELP-MMP-2i protein was determined using the Dahl salt-sensitive rat model of renal injury. A potent and selective inhibition of MMP-2 by ELP-MMP-2i was observed, and the construct containing the smallest ELP domain was the most potent. All fusion proteins targeted the kidneys, with the smallest fusion protein having the highest bioavailability after subcutaneous delivery. Efficacy studies with the optimized ELP-MMP-2i protein revealed that ELP-MMP-2i treatment reduced proteinuria, albuminuria, and renal fibrosis compared with vehicle-treated hypertensive rats. Renally targeted delivery of an MMP-2 inhibitor using the novel ELP drug delivery system has the potential to prevent hypertension-induced renal fibrosis and could represent a future therapy for chronic kidney disease. SIGNIFICANCE STATEMENT: To the authors' knowledge, this is the first study to demonstrate the ability of a kidney-targeted selective matrix metalloproteinase-2 inhibitory peptide biologic to reduce renal fibrosis in a renal injury model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.